These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8642360)

  • 21. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 22. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
    Gerlach M; Riederer P; Vogt H
    BMJ; 1996 Mar; 312(7032):704; author reply 704-5. PubMed ID: 8597750
    [No Abstract]   [Full Text] [Related]  

  • 24. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 25. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
    Birkmayer W; Riederer P
    Adv Neurol; 1984; 40():475-81. PubMed ID: 6421111
    [No Abstract]   [Full Text] [Related]  

  • 26. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 27. Levodopa for Parkinson's disease.
    Devos D; Moreau C; Destée A
    N Engl J Med; 2009 Feb; 360(9):935-6; author reply 936. PubMed ID: 19246370
    [No Abstract]   [Full Text] [Related]  

  • 28. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
    MacMahon DG; Bland R
    BMJ; 1996 Mar; 312(7032):703; author reply 704-5. PubMed ID: 8597748
    [No Abstract]   [Full Text] [Related]  

  • 30. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
    Djaldetti R; Ziv I; Melamed E
    Isr J Med Sci; 1996 Dec; 32(12):1224-7. PubMed ID: 9007159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
    Mäki-Ikola O; Kilkku O; Heinonen E
    BMJ; 1996 Mar; 312(7032):702; author reply 704-5. PubMed ID: 8597744
    [No Abstract]   [Full Text] [Related]  

  • 32. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2003 Dec; (10):1582-98. PubMed ID: 15555162
    [No Abstract]   [Full Text] [Related]  

  • 33. 3-O-Methyldopa in Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Adv Neurol; 1974; 5():309-15. PubMed ID: 4440579
    [No Abstract]   [Full Text] [Related]  

  • 34. [Changes in lipid metabolism in patients with Parkinson disease after combined treatment with L-deprenil (iumex) and antiparkinson drugs].
    Alimov IIu; Nazhmidinova MN; Ganiev KhG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(12):35-8. PubMed ID: 1965367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MPTP: clinical implications.
    Stern G
    J Neural Transm Suppl; 1986; 20():77-81. PubMed ID: 3091763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 38. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2004 Jun; (11):1736-54. PubMed ID: 15652077
    [No Abstract]   [Full Text] [Related]  

  • 39. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.